Kura Oncology logo

Kura Oncology (KURA) Q1 2026 Earnings

KURA·Reported May 12, 2026·After market close

Kura Oncology reported Q1 2026 revenue of $18.3M (+29.5% YoY), missed analyst consensus of $26.0M by $7.7M. Diluted EPS came in at $-0.83 (-25.8% YoY), beat the $-0.88 consensus by $0.05.

Revenue
$18.3Mmissed by $7.7M
Consensus: $26.0M
Diluted EPS
$-0.83beat by $0.05
Consensus: $-0.88
SEC

SEC Filings

Earnings release8-K · 0001193125-26-219422
Quarterly report10-Q · 0001193125-26-219481

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Kura Oncology's Q1 2026 earnings report.

Kura Oncology (KURA) reported Q1 2026 earnings on May 12, 2026 after market close.

Kura Oncology reported revenue of $18.3M and diluted EPS of $-0.83 for Q1 2026.

Revenue missed the consensus estimate of $26.0M by $7.7M. EPS beat the consensus estimate of $-0.88 by $0.05.

Compared to the same quarter a year prior, revenue grew 29.5% from $14.1M a year earlier and diluted EPS declined 25.8% from $-0.66.

You can read the 8-K earnings release (0001193125-26-219422) and the 10-Q periodic report (0001193125-26-219481) directly on SEC EDGAR. The filing index links above go to sec.gov.